Lilly’s Strong Alimta Pivotal Study Obviated Need For Second Trial – FDA
This article was originally published in Pharmaceutical Approvals Monthly
The significant survival benefit seen with Alimta in Lilly’s sole pivotal mesothelioma trial appears to have obviated FDA’s need for efficacy data from a second study.
You may also be interested in...
Response is not an acceptable primary endpoint for approval in mesothelioma, FDA said in review documents for Lilly’s oncologic agent Alimta.
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011